The Australian government, through the Therapeutic Goods Administration (TGA), has mandated that supplements containing more than 10 mg of vitamin B6 must carry a warning about the risk of peripheral neuropathy. This decision was based on reports of neuropathy occurring even at lower doses, especially when multiple supplements containing vitamin B6 were consumed concurrently. https://www.tga.gov.au/news/safety-updates/peripheral-neuropathy-supplementary-vitamin-b6-pyridoxine
Question will also resolve as true if US takes a more stringent action, such as banning sale of vitamin b6 above certain doses, in a given year.
If we all still care in 2037 and this hasn’t happened yet, will resolve as Other/Never.
1,000No U.S. action yet requiring warning labels on vitamin B6 supplements for peripheral neuropathy risk (or any stricter dose limits/bans). The FDA’s recent related move (March 2026) went the other direction—requiring warnings about deficiency risk and seizures from carbidopa/levodopa Parkinson’s drugs:
Closest parallel developments:
Canada (Health Canada, March–June 2026): Safety review found a possible association between vitamin B6 natural health products at ≥10 mg/day and peripheral neuropathy. Updated the Multi-Vitamin/Mineral Supplements Monograph; labels on affected products are expected to include information on sensory symptoms (numbness, tingling, pain in extremities) plus advice to stop and consult a professional.
Australia (TGA): Existing requirement for neuropathy warnings on products >10 mg/day remains in force. Higher-dose (50–200 mg) products are being rescheduled as Pharmacist Only from 1 June 2027.
Good overview of the Canadian and Australian moves (Science-Based Medicine, 13 Aug 2026):
https://sciencebasedmedicine.org/new-cautions-about-vitamin-b6-and-peripheral-neuropathy/
Additional context on rising adverse-event reports and international regulatory pressure:
U.S. adverse-event numbers have climbed (dozens of serious reports in recent years), but under DSHEA the bar for mandatory specific warnings is higher than in Canada or Australia. Current market odds still lean heavily toward Other/Never by 2037, which remains consistent with the lack of any open FDA process on excess-B6 labeling.
Its good to know that the tga are prudent enough to recognize this, there are many things that go wrong if abundant... Also, it is cheap to produce and it is not "profitable", so lets hope that the autorities would be less shy and raise awareness about these megavitamin syndromes ...